To the editor

New England Journal of Medicine

Volumn 373, Issue 15, 2015, Pages 1476-

  Singh, Jagdeep S ^a   Struthers, Allan D ^a   Lang, Chim C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR RISK; DRUG USE; HEART INFARCTION; HUMAN; LETTER; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; ACUTE CORONARY SYNDROME; BLOOD; FEMALE; MALE;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; SIMVASTATIN;

EID: 84943560343     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1509363     Document Type: Letter

References (4)

1. Jarcho JA, Keaney JF Jr. Proof that lower is better-LDL cholesterol and IMPROVE-IT. N Engl J Med 2015;372:2448-50.
2. National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. July 2014 (http://www.nice.org.uk/ guidance/cg181).
3. Pauriah M, Elder DHJ, Ogston S, et al. High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: A population-based study. Heart 2014;100:867-72.
4. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind randomised trial. Lancet 2010;376:1658-69.